AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope
Rock Bottom Prices May Tempt Big Pharma
AstraZeneca's Alexion division has picked up the company at a bargain price of $68m, even while paying six times its market value. 
